Remifentanil is a strong pain reliever and sedative used during surgery and other medical procedures to keep patients comfortable and help them stay calm while under anesthesia.[2] Ultiva is currently approved and in use across 50 indications[4].[1]
Ultiva is one of 668 small molecule programs targeting Premature Birth. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
254 competitors in Colorectal Cancer
Stivarga
Fudr
Adrucil
Wellcovorin
Ultiva
Acetylsalicylic Acid
XL092
Huaier Granule
PD-1 Monoclonal Antibody
Cytokine-Induced Killer Cells
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Jul 12, 1996
ULTIVA
NDA NDA020630
Jun 23, 1999
ULTIVA
NDA NDA020630
Oct 15, 1999
ULTIVA
NDA NDA020630
Nov 23, 1999
ULTIVA
NDA NDA020630
Sep 19, 2000
ULTIVA
NDA NDA020630
Nov 19, 2001
ULTIVA
NDA NDA020630
Oct 3, 2002
ULTIVA
NDA NDA020630
Dec 20, 2002
ULTIVA
NDA NDA020630
Mar 8, 2004
ULTIVA
NDA NDA020630
Jun 11, 2013
ULTIVA
NDA NDA020630
Jan 12, 2016
ULTIVA
NDA NDA020630
Dec 16, 2016
ULTIVA
NDA NDA020630
Jun 21, 2018
ULTIVA
NDA NDA020630
Oct 7, 2019
ULTIVA
NDA NDA020630
Dec 15, 2023
ULTIVA
NDA NDA020630
Dec 22, 2025
ULTIVA
NDA NDA020630
Dec 22, 2025
ULTIVA
NDA NDA020630
Sources
Details